Finally, we found that the “active” but not “inactive” cofilin mediates tauopathy, microtubule deregulation, and synaptic dysfunction in the Tau-P301S model, indicating that the activation cycle of cofilin represents a potential therapeutic opportunity for AD and other tauopathies. Here, MAPT is linked to tauopathy.